- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - CT0596 RECEIVED IND CLEARANCE FROM THE NMPA FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE ... | 3 | HKEx | ||
| 17.07. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 15.07. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON SATRI-CEL ACCEPTED FOR POSTER PRESENTATION AT ESMO CONGRESS 2026 | 1 | HKEx | ||
| 07.07. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 26.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY | 1 | HKEx | ||
| 24.06. | China's CARsgen Slides for Second Day on Hefty Price Tag for World's First Solid Tumor CAR-T Therapy | 3 | Yicai Global | ||
| 22.06. | CARsgen makes history as China approves world's first CAR-T therapy for solid tumors | 1 | FiercePharma | ||
| 22.06. | CARSgen bags world-first approval for solid tumour CAR-T | 2 | pharmaphorum | ||
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.06. | CARsgen's Solid-Tumor CAR-T Therapy Nears China Approval, a Global First | 1 | Yicai Global | ||
| 22.06. | CARSGEN-B (02171): INSIDE INFORMATION ANNOUNCEMENT - THE NMPA APPROVES THE NEW DRUG APPLICATION FOR THE CLAUDIN18.2 CAR T-CELL THERAPY PRODUCT SATRICABTAGENE ... | 1 | HKEx | ||
| 15.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON CT0596 AND CT1190B AT 2026 EHA ANNUAL CONGRESS | 1 | HKEx | ||
| 01.06. | CARsgen Therapeutics: Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting | 92 | PR Newswire | SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 01.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON SATRI-CEL AT THE 2026 ASCO ANNUAL MEETING | 1 | HKEx | ||
| 26.05. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 26.05. | CARSGEN-B (02171): COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 4 | HKEx | ||
| 22.05. | CARSGEN-B (02171): NINTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 5 | HKEx | ||
| 22.05. | CARSGEN-B (02171): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2026 | - | HKEx | ||
| 22.05. | CARSGEN-B (02171): CLARIFICATION ANNOUNCEMENT | 1 | HKEx | ||
| 15.05. | CARSGEN-B (02171): PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 27.04. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON CT0596 AND CT1190B ACCEPTED FOR POSTER PRESENTATION AT 2026 EHA ANNUAL CONGRESS | - | HKEx |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,21 | -0,01 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| QIAGEN | 36,370 | +0,90 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 21,850 | 0,00 % | Amylyx demystifies post-bariatric hypoglycemia with patient education website | ||
| ENLIVEN THERAPEUTICS | 59,70 | 0,00 % | Enliven Therapeutics GAAP EPS of -$0.49 misses by $0.10 | ||
| VERA THERAPEUTICS | 30,380 | +0,10 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TREVI THERAPEUTICS | 18,650 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,170 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,300 | +0,07 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 47,290 | -0,11 % | Sionna Therapeutics Aktie markiert Rekordhoch bei 51,63 USD | ||
| TYRA BIOSCIENCES | 25,710 | 0,00 % | Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights | - Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -
- Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in... ► Artikel lesen | |
| ERASCA | 18,615 | -0,03 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 318,88 | -0,11 % | Praxis Precision Medicines Q2 2026 Earnings Preview | ||
| BICARA THERAPEUTICS | 25,890 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET | ||
| ARCUTIS BIOTHERAPEUTICS | 27,000 | -0,37 % | Arcutis Q2 2026 slides: profitability milestone, revenue jumps 59% | ||
| CG ONCOLOGY | 72,41 | -0,01 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen |
CARSGEN THERAPEUTICS HOLDINGS LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.